GLP-1 & Incretin Science

What Is Oxyntomodulin? Nature's Dual Agonist

UKPWritten and published by UK Peptides2 min readUpdated 3 cited sources

The short answer

Oxyntomodulin is a naturally occurring 37-residue gut peptide produced from proglucagon that activates both the GLP-1 and glucagon receptors. It is the endogenous proof that combined GLP-1 and glucagon agonism is physiologically coherent, and the precedent behind survodutide and mazdutide.

Key facts

Type
Endogenous gut peptide
Length
37 residues
Molecular weight
~4,422 Da
Molecular formula
C192H295N59O60S
PubChem CID
16144019
Precursor
Proglucagon
Receptors
GLP-1R and glucagon receptor
Drugs built on it
Survodutide, mazdutide

Where it comes from

Oxyntomodulin is produced by post-translational processing of proglucagon in intestinal L cells, the same precursor protein that yields GLP-1. Which peptides emerge depends on which processing enzymes are present, which is why the pancreas and the intestine generate different products from identical genetic material. Oxyntomodulin is released after meals alongside GLP-1.

Why it activates two receptors

Its sequence contains the full glucagon sequence with an eight-residue C-terminal extension. That shared ancestry means it retains meaningful affinity for the glucagon receptor while also engaging GLP-1R, though with lower potency at each than the dedicated ligands. It is not a strong agonist at either. It is a moderate agonist at both.

Research material referenced

Retatrutide 10mg, third-party HPLC tested

Buy Retatrutide · £59.99

Why that combination is interesting rather than contradictory

Glucagon raises blood glucose, so pairing it with GLP-1 looks self-defeating. Physiologically it is not: glucagon also increases energy expenditure and drives hepatic lipid oxidation, and sufficient concurrent GLP-1 signalling offsets the glycaemic effect. Oxyntomodulin demonstrates that the body itself deploys this combination, which is the strongest possible argument that the pharmacology is coherent.

What was built on it

Survodutide and mazdutide are engineered GLP-1/glucagon dual agonists, with mazdutide derived from oxyntomodulin directly. Retatrutide extends the same logic by adding GIP on top, making a triple agonist. Every glucagon-containing incretin drug traces its rationale to this peptide.

Why oxyntomodulin itself is not a drug

It has a very short half-life, being subject to DPP-4 and rapid clearance like other native gut peptides, and its potency at each receptor is modest. Engineering was required on both counts: protease resistance and albumin binding for duration, and sequence optimisation to tune the balance of activity between the two receptors deliberately rather than accepting what physiology provides.

Frequently asked questions

Is oxyntomodulin the same as glucagon?

No, but it contains the glucagon sequence plus an eight-residue C-terminal extension, which is why it retains glucagon receptor activity.

Is oxyntomodulin available as a medicine?

No. Its short half-life and modest potency at each receptor mean engineered analogues were developed instead.

Why do GLP-1 and glucagon agonism combine usefully?

Glucagon increases energy expenditure and hepatic lipid oxidation; sufficient GLP-1 signalling offsets its glucose-raising effect. Oxyntomodulin shows the body already uses this combination.

Continue researching

Related guides and reference material.

Primary sources & clinical trials

Published papers, trial registrations, regulator pages and company announcements. Links open the original.

UKP

Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).

Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.

Corrections log

More GLP-1 & Incretin Science articles

Research use only. The information above is provided for scientific and educational reference. Compounds referenced are not approved for human use and are supplied for in vitro research or reference-material purposes only. No efficacy, safety, or therapeutic claims are made.